1. Home
  2. SPCE vs MOLN Comparison

SPCE vs MOLN Comparison

Compare SPCE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virgin Galactic Holdings Inc.

SPCE

Virgin Galactic Holdings Inc.

HOLD

Current Price

$2.99

Market Cap

226.9M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.09

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SPCE
MOLN
Founded
2017
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Transportation Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
226.9M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SPCE
MOLN
Price
$2.99
$4.09
Analyst Decision
Hold
Hold
Analyst Count
6
1
Target Price
$9.22
$3.75
AVG Volume (30 Days)
3.8M
2.3K
Earning Date
11-13-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,661,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,656.89
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$3.36
52 Week High
$6.82
$5.91

Technical Indicators

Market Signals
Indicator
SPCE
MOLN
Relative Strength Index (RSI) 36.28 46.91
Support Level $3.71 $4.13
Resistance Level $4.57 $4.57
Average True Range (ATR) 0.28 0.16
MACD -0.09 -0.02
Stochastic Oscillator 7.05 23.91

Price Performance

Historical Comparison
SPCE
MOLN

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: